Clinical Trials Directory

Trials / Completed

CompletedNCT04917588

Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip Augmentation

A Prospective, Open-label, Multicentre, Randomized Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip Augmentation

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
114 (actual)
Sponsor
Croma-Pharma GmbH · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This is a prospective, open-label, multicentre, randomized study conducted to evaluate the effectiveness, safety and long-term safety of Saypha® FILLER Lidocaine for lip augmentation.

Detailed description

Following informed consent and screening, eligible subjects with moderate to severe deficiency of lip volume will be randomized to receive Saypha® FILLER Lidocaine from 1 of 2 manufacturing sites. The device will be injected into the submucosa of the lips, and subjects will return for follow-up assessments at Week 3, 6, 26, 52 and optional at Week 76 after the treatment. A Touch-up treatment may be done at Week 3, if deemed appropriate by the investigator. The performance of the investigational device will be evaluated by the investigator by assessing severity using the LFS, Lip Fullness Scale, at Week 6, 26, 52 after the treatment and optional at Week 76 and in comparison to Day 0. The upper and lower lip will be graded separately. Telephone visits will be performed approximately 24 hours post-administration to monitor possible adverse events. In case any adverse events are reported during the telephone visits an unscheduled visit should be performed.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTSaypha® FILLER Lidocaine (HQ)Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
COMBINATION_PRODUCTSaypha® FILLER Lidocaine (C1)Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.

Timeline

Start date
2020-07-28
Primary completion
2020-12-14
Completion
2022-04-06
First posted
2021-06-08
Last updated
2025-03-14
Results posted
2025-03-14

Locations

3 sites across 1 country: Austria

Source: ClinicalTrials.gov record NCT04917588. Inclusion in this directory is not an endorsement.